HOME Top Market Reports Biomarkers Market - ([Discovery Technologies - Proteomics, Genomics, Imaging, Bioinformatics], Validation Services, Applications [drug development, personalized medicine], Diseases [Oncology, Cardiology, Neurology]) - Global Trends & Forecasts (2013 – 2018)

Biomarkers Market - ([Discovery Technologies - Proteomics, Genomics, Imaging, Bioinformatics], Validation Services, Applications [drug development, personalized medicine], Diseases [Oncology, Cardiology, Neurology]) - Global Trends & Forecasts (2013 – 2018)

By: marketsandmarkets.com
Publishing Date: September 2013
Report Code: BT 2120

 

Enquiry Before Buying
Analyst Briefing  
purchase report
download pdf  request for customisation


The global biomarkers market showcases high growth potential in the near future with an estimated CAGR of 18.5% from 2013 to 2018, to reach $40.8 billion by 2018. Current industry trends such as advancements in discovery technologies, government initiatives, and grants for biomarker research activities, and the rising demand for personalized medicine are the key factors that contribute to the growth of this market. However, the need for high capital investment for biomarker discovery, low benefit-cost ratio, a cumbersome biomarker validation, and testing process are a few of the critical factors that restrain the growth of the market.

The report categorizes the biomarkers market on the basis of discovery technologies (omics technology, imaging technology, and bioinformatics), biomarker services, applications, and disease indications. The omics technology segment holds the largest share of ~75% of the biomarker discovery market, primarily due to the increase in adoption of proteomics and genomics technologies, globally.

The emerging Asia-Pacific region exhibits high growth opportunities for industry participants. Growing economies such as China and India are experiencing an increasing rate of biomarkers research activities. This is attributed to the rising number of contract research organizations and the low cost of conducting clinical trials in Asia-Pacific nations when compared to developed countries. Increasing popularity of personalized medicine and the growing importance of companion diagnostics are further opening new growth opportunities for the development of novel biomarkers.

Roche Diagnostics Limited (Switzerland), Johnson & Johnson (U.S.), GlaxoSmithKline Plc. (U.K.), Siemens Healthcare (Germany), Abbott Laboratories Inc. (U.S.), GE Healthcare (U.K.), Affymetrix Inc. (U.S.), Epigenomics AG (Germany), Eisai Co. Ltd. (Japan), Bio-Rad Laboratories Inc. (U.S.), Eli Lilly and Company (U.S.), Merck & Co. (U.S.) are a few of the key players in this market. Partnerships, agreements, collaborations, & mergers and acquisitions are the key business strategies adopted by market participants to ensure their growth in the market.

TABLE OF CONTENTS  
  
1 INTRODUCTION
 
  1.1 KEY TAKE-AWAYS 
  1.2 REPORT DESCRIPTION 
  1.3 STAKEHOLDERS 
  1.4 RESEARCH METHODOLOGY 
      1.4.1 MARKET SIZE 
      1.4.2 KEY DATA POINTS FROM SECONDARY SOURCES 
      1.4.3 ASSUMPTIONS 
  
2 EXECUTIVE SUMMARY 
  
3 MARKET OVERVIEW 

  3.1 DEFINITION OF BIOMARKERS 
  3.2 BIOMARKERS & ITS TYPES 
  3.3 BIOMARKERS MARKET 
      3.3.1 MARKET SEGMENTATION 
      3.3.2 CHALLENGES & OPPORTUNITIES 
            3.3.2.1 Challenges 
                    3.3.2.1.1 Variability 
                    3.3.2.1.2 Ethical considerations & acceptability 
            3.3.2.2 Opportunities 
                    3.3.2.2.1 Personalized medicine 
                    3.3.2.2.2 Companion diagnostics 
      3.3.3 DRIVERS & RESTRAINTS 
            3.3.3.1 Drivers 
                    3.3.3.1.1 High demand boosts the growth of the biomarkers market globally 
                    3.3.3.1.2 Strategic collaborations lead to increasing applications in the market 
                    3.3.3.1.3 Technological advances contribute to growth 
                    3.3.3.1.4 The rising prevalence of the disease forms 
                    3.3.3.1.5 FDA support for biomarkers development 
            3.3.3.2 Restraints 
                    3.3.3.2.1 Low capital investment & cost-benefit hinders growth of biomarkers 
                    3.3.3.2.2 Biomarkers not a profitable market for small organizations 
                    3.3.3.2.3 Sample collection & storage 
                    3.3.3.2.4 Limited biomarkers validation 
                    3.3.3.2.5 Need for new R&D models with greater precision & flexibility 
  
4 GLOBAL BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES 
  4.1 INTRODUCTION 
  4.2 IMAGING TECHNOLOGIES FOR BIOMARKERS DISCOVERY 
      4.2.1 POSITRON EMISSION TOMOGRAPHY (PET) 
      4.2.2 SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY(SPECT) 
      4.2.3 ULTRASOUND 
      4.2.4 MAGNETIC RESONANCE IMAGING (MRI) 
      4.2.5 COMPUTED TOMOGRAPHY (CT) 
  4.3 OMICS TECHNOLOGIES FOR BIOMARKERS DISCOVERY 
      4.3.1 PROTEOMICS 
            4.3.1.1 Mass spectrometry 
                    4.3.1.1.1 MALDI mass spectrometry 
                    4.3.1.1.2 Imaging mass spectrometry 
            4.3.1.2 2D Gel Electrophoresis 
            4.3.1.3 Protein microarray technology 
            4.3.1.4 Antibody array technology 
            4.3.1.5 Peptide array technology 
      4.3.2 GENOMICS 
            4.3.2.1 Whole genome sequencing 
            4.3.2.2 Genotyping 
            4.3.2.3 Epigenetics 
      4.3.3 TRANSCRIPTOMICS 
            4.3.3.1 Microarrays 
            4.3.3.2 Gene expression profiling 
      4.3.4 METABOLOMICS 
            4.3.4.1 Capillary electrophoresis 
            4.3.4.2 Mass spectrometry based kits 
            4.3.4.3 Nuclear Magnetic Resonance(NMR) 
  4.4 BIOINFORMATICS 
      4.4.1 CLUSTER ANALYSIS 
      4.4.2 STATISTICAL ANALYSIS 
      4.4.3 CELL SIGNAL PATHWAYS 
      4.4.4 COMPUTER AIDED DESIGN 
      4.4.5 DATA MINING 
      4.4.6 PROTEIN INTERACTION MAPS 
  
5 SERVICES MARKET OF BIOMARKERS 
  5.1 INTRODUCTION 
  5.2 CLINICAL 
      5.2.1 SAMPLE PREPARATION 
      5.2.2 ASSAY DEVELOPMENT 
      5.2.3 BIOMARKERS VALIDATION & TESTING 
            5.2.3.1 Feasibility Studies and choice of assay & biomarkers 
            5.2.3.2 Long lead time required for Biomarkers Assay preparation 
  5.3 BIOINFORMATICS 
      5.3.1 FUNCTIONAL GENOMICS & PROTEOMICS DRIVE THE DEMAND FOR BIOINFORMATICS 
  
6 BIOMARKERS APPLICATION MARKET 
  6.1 INTRODUCTION 
  6.2 DRUG DISCOVERY & DEVELOPMENT 
      6.2.1 CLINICAL TRIALS 
            6.2.1.1 Preclinical Development 
            6.2.1.2 Phase I drug development 
            6.2.1.3 Phase II drug development 
            6.2.1.4 Phase III drug development 
            6.2.1.5 Phase IV drug development 
  6.3 PERSONALIZED MEDICINE 
  6.4 MOLECULAR DIAGNOSTICS 
      6.4.1 MOLECULAR DIAGNOSTICS IS A DYNAMIC & RAPIDLY BROADENING MARKET 
      6.4.2 TRENDS IN THE DIAGNOSTICS MARKET 
      6.4.3 CHALLENGES 
            6.4.3.1 Nucleic acids pose a challenge to the molecular diagnostics field 
            6.4.3.2 Molecular diagnostics market lacks a collaborated effort 
      6.4.4 DRIVER 
            6.4.4.1 Increase in the incidence of diseases spurs the growth of the diagnostics market 
      6.4.5 RESTRAINT 
            6.4.5.1 The “interest-information” restricts growth of molecular diagnostics 
      6.4.6 MOLECULAR DIAGNOSTICS IN MAJOR INDICATIONS 
            6.4.6.1 Oncology 
            6.4.6.2 Cardiology 
            6.4.6.3 Neurology 
            6.4.6.4 Other treatment areas 
      6.4.7 BIOMARKERS IN DIAGNOSTICS 
      6.4.8 BENEFITS OF MOLECULAR DIAGNOSTICS 
  
7 BIOMARKERS INDICATION MARKET 
  7.1 INTRODUCTION 
  7.2 ONCOLOGY BIOMARKERS MARKET 
      7.2.1 ONCOLOGY BIOMARKERS DISCOVERY MARKET 
            7.2.1.1 Genomics 
            7.2.1.2 Proteomics 
            7.2.1.3 Metabolomics 
            7.2.1.4 Transcriptomics 
            7.2.1.5 Other Omics 
            7.2.1.6 Imaging 
      7.2.2 DRUG DISCOVERY & DEVELOPMENT 
      7.2.3 CANCER TYPES 
            7.2.3.1 Ovarian Cancer 
            7.2.3.2 Breast Cancer 
            7.2.3.3 Bladder Cancer 
            7.2.3.4 Cervical Cancer 
            7.2.3.5 Prostate Cancer 
            7.2.3.6 Lung Cancer 
            7.2.3.7 Colorectal Cancer 
  7.3 CARDIOLOGY BIOMARKERS MARKET 
      7.3.1 CARDIOLOGY BIOMARKERS DISCOVERY MARKET 
            7.3.1.1 Genomics 
            7.3.1.2 Proteomics 
            7.3.1.3 Metabolomics 
            7.3.1.4 Transcriptomics 
            7.3.1.5 Imaging 
            7.3.1.6 Bioinformatics 
      7.3.2 DRUG DISCOVERY & DEVELOPMENT 
      7.3.3 CARDIAC MARKERS, BY DISEASE TYPES 
            7.3.3.1 Acute Coronary Syndrome 
            7.3.3.2 Coronary artery disease 
            7.3.3.3 Stroke 
      7.3.4 CARDIOLOGY BIOMARKERS USED IN THE MARKET 
  7.4 NEUROLOGY BIOMARKERS MARKET 
      7.4.1 NEUROLOGY BIOMARKERS DISCOVERY MARKET 
            7.4.1.1 Omics technologies 
            7.4.1.2 Imaging Technologies 
      7.4.2 DRUG DISCOVERY & DEVELOPMENT 
      7.4.3 DISEASE TYPES 
            7.4.3.1 Alzheimer’s disease 
            7.4.3.2 Parkinson’s disease 
            7.4.3.3 Multiple sclerosis 
            7.4.3.4 Schizophrenia 
            7.4.3.5 Amyotrophic Lateral Sclerosis 
            7.4.3.6 Epilepsy 
  7.5 OTHER INDICATIONS BIOMARKERS MARKET 
      7.5.1 OTHER INDICATION BIOMARKERS DISCOVERY MARKET 
            7.5.1.1 Omics technologies 
            7.5.1.2 Imaging technologies 
      7.5.2 DRUG DISCOVERY & DEVELOPMENT 
  7.6 DISEASE TYPES 
      7.6.1 HIV 
            7.6.1.1 Immunological & Virological Markers in HIV Infection 
  7.7 RENAL FAILURE 
  7.8 ARTHRITIS 
  7.9 TUBERCULOSIS 
  7.10 DIABETES 
  
8 GEOGRAPHICAL ANALYSIS 
  8.1 INTRODUCTION 
  8.2 NORTH AMERICA 
  8.3 EUROPE 
  8.4 ASIA 
  8.5 ROW 
  
9 COMPETITIVE LANDSCAPE 
  9.1 KEY STRATEGIES 
  9.2 MERGERS & ACQUISITIONS 
  9.3 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES 
  9.4 NEW PRODUCTS LAUNCH 
  9.5 OTHER DEVELOPMENTS 
  
10 COMPANY PROFILES 
  10.1 ABBOTT LABORATORIES 
      10.1.1 OVERVIEW 
      10.1.2 FINANCIALS 
      10.1.3 PRODUCTS & SERVICES 
      10.1.4 STRATEGY 
      10.1.5 DEVELOPMENTS 
  10.2 ABCODIA LTD 
      10.2.1 OVERVIEW 
      10.2.2 FINANCIALS 
      10.2.3 PRODUCTS & SERVICES 
      10.2.4 STRATEGY 
      10.2.5 DEVELOPMENTS 
  10.3 AFFYMETRIX INC 
      10.3.1 OVERVIEW 
      10.3.2 FINANCIALS 
      10.3.3 PRODUCTS & SERVICES 
      10.3.4 STRATEGY 
      10.3.5 DEVELOPMENTS 
  10.4 AGILENT TECHNOLOGIES INC 
      10.4.1 OVERVIEW 
      10.4.2 FINANCIALS 
      10.4.3 PRODUCTS & SERVICES 
      10.4.4 STRATEGY 
      10.4.5 DEVELOPMENTS 
  10.5 AMGEN INC 
      10.5.1 OVERVIEW 
      10.5.2 FINANCIALS 
      10.5.3 PRODUCTS & SERVICES 
      10.5.4 STRATEGY 
      10.5.5 DEVELOPMENT 
  10.6 ASTRAZENECA PLC 
      10.6.1 OVERVIEW 
      10.6.2 FINANCIALS 
      10.6.3 PRODUCTS & SERVICES 
      10.6.4 STRATEGY 
      10.6.5 DEVELOPMENTS 
  10.7 AUGUREX LIFE SCIENCES CORP 
      10.7.1 OVERVIEW 
      10.7.2 FINANCIALS 
      10.7.3 PRODUCTS & SERVICES 
      10.7.4 STRATEGY 
      10.7.5 DEVELOPMENTS 
  10.8 AUSHON BIOSYSTEMS INC 
      10.8.1 OVERVIEW 
      10.8.2 FINANCIALS 
      10.8.3 PRODUCTS & SERVICES 
      10.8.4 STRATEGY 
      10.8.5 DEVELOPMENTS 
  10.9 BAYER AG 
      10.9.1 OVERVIEW 
      10.9.2 FINANCIALS 
      10.9.3 PRODUCTS & SERVICES 
      10.9.4 STRATEGY 
      10.9.5 DEVELOPMENTS 
  10.1 BECKMAN COULTER INC 
      10.10.1 OVERVIEW 
      10.10.2 FINANCIALS 
      10.10.3 PRODUCTS & SERVICES 
      10.10.4 STRATEGY 
      10.10.5 DEVELOPMENTS 
  10.11 BGI 
      10.11.1 OVERVIEW 
      10.11.2 FINANCIALS 
      10.11.3 PRODUCTS & SERVICES 
      10.11.4 STRATEGY 
      10.11.5 DEVELOPMENTS 
  10.12 BIOCRATES LIFE SCIENCES AG 
      10.12.1 OVERVIEW 
      10.12.2 FINANCIALS 
      10.12.3 PRODUCTS & SERVICES 
      10.12.4 STRATEGY 
      10.12.5 DEVELOPMENTS 
  10.13 BIOMARKERS STRATEGIES 
      10.13.1 OVERVIEW 
      10.13.2 FINANCIALS 
      10.13.3 PRODUCTS & SERVICES 
      10.13.4 STRATEGY 
      10.13.5 DEVELOPMENTS 
  10.14 BIOSYSTEMS INTERNATIONAL 
      10.14.1 OVERVIEW 
      10.14.2 FINANCIALS 
      10.14.3 PRODUCTS & SERVICES 
      10.14.4 STRATEGY 
      10.14.5 DEVELOPMENTS 
  10.15 BRISTOL-MYERS SQUIBB 
      10.15.1 OVERVIEW 
      10.15.2 FINANCIALS 
      10.15.3 PRODUCTS & SERVICES 
      10.15.4 STRATEGY 
      10.15.5 DEVELOPMENTS 
  10.16 CRESCENDO BIOSCIENCE 
      10.16.1 OVERVIEW 
      10.16.2 FINANCIALS 
      10.16.3 PRODUCTS & SERVICES 
      10.16.4 STRATEGY 
      10.16.5 DEVELOPMENTS 
  10.17 EISAI CO. LTD. 
      10.17.1 OVERVIEW 
      10.17.2 FINANCIALS 
      10.17.3 PRODUCTS & SERVICES 
      10.17.4 STRATEGY 
      10.17.5 DEVELOPMENTS 
  10.18 EPIONTIS GMBH 
      10.18.1 OVERVIEW 
      10.18.2 FINANCIALS 
      10.18.3 PRODUCTS & SERVICES 
      10.18.4 DEVELOPMENTS 
  10.19 EPISTEM HOLDINGS PLC 
      10.19.1 OVERVIEW 
      10.19.2 FINANCIALS 
      10.19.3 PRODUCTS & SERVICES 
      10.19.4 STRATEGY 
      10.19.5 DEVELOPMENTS 
  10.20 EUROGENTEC S.A. 
      10.20.1 OVERVIEW 
      10.20.2 FINANCIALS 
      10.20.3 PRODUCTS & SERVICES 
      10.20.4 STRATEGY 
      10.20.5 DEVELOPMENTS 
  10.21 EVOTEC AG 
      10.21.1 OVERVIEW 
      10.21.2 FINANCIALS 
      10.21.3 PRODUCTS & SERVICES 
      10.21.4 STRATEGY 
      10.21.5 DEVELOPMENTS 
  10.22 GLAXOSMITHKLINE PLC 
      10.22.1 OVERVIEW 
      10.22.2 FINANCIALS 
      10.22.3 PRODUCTS & SERVICES 
      10.22.4 STRATEGY 
      10.22.5 DEVELOPMENTS 
  10.23 IPSEN 
      10.23.1 OVERVIEW 
      10.23.2 FINANCIALS 
      10.23.3 PRODUCTS & SERVICES 
      10.23.4 STRATEGY 
      10.23.5 DEVELOPMENTS 
  10.24 JOHNSON & JOHNSON 
      10.24.1 OVERVIEW 
      10.24.2 FINANCIALS 
      10.24.3 PRODUCTS & SERVICES 
      10.24.4 STRATEGY 
      10.24.5 DEVELOPMENTS 
  10.25 MERCK & CO. 
      10.25.1 OVERVIEW 
      10.25.2 FINANCIALS 
      10.25.3 PRODUCTS & SERVICES 
      10.25.4 STRATEGY 
      10.25.5 DEVELOPMENTS 
  10.26 MICROMEDIC TECHNOLOGIES LTD 
      10.26.1 OVERVIEW 
      10.26.2 PRODUCTS & SERVICES 
      10.26.3 STRATEGY 
      10.26.4 DEVELOPMENTS 
  10.27 MYRIAD GENETICS INC 
      10.27.1 OVERVIEW 
      10.27.2 FINANCIALS 
      10.27.3 PRODUCTS & SERVICES 
      10.27.4 STRATEGY 
      10.27.5 DEVELOPMENTS 
  10.28 NEXTGEN SCIENCES INC 
      10.28.1 OVERVIEW 
      10.28.2 FINANCIALS 
      10.28.3 PRODUCTS & SERVICES 
      10.28.4 STRATEGY 
      10.28.5 DEVELOPMENTS 
  10.29 NOVARTIS INTERNATIONAL AG 
      10.29.1 OVERVIEW 
      10.29.2 FINANCIALS 
      10.29.3 PRODUCTS & SERVICES 
      10.29.4 STRATEGY 
      10.29.5 DEVELOPMENTS 
  10.30 OCIMUM BIOSOLUTIONS LTD 
      10.30.1 OVERVIEW 
      10.30.2 FINANCIALS 
      10.30.3 PRODUCTS & SERVICES 
      10.30.4 STRATEGY 
      10.30.5 DEVELOPMENTS 
  10.31 PFIZER INC 
      10.31.1 OVERVIEW 
      10.31.2 FINANCIALS 
      10.31.3 PRODUCTS & SERVICES 
      10.31.4 STRATEGY 
      10.31.5 DEVELOPMENTS 
  10.32 PRONOTA NV 
      10.32.1 OVERVIEW 
      10.32.2 FINANCIALS 
      10.32.3 PRODUCTS & SERVICES 
      10.32.4 STRATEGY 
      10.32.5 DEVELOPMENTS 
  10.33 QUINTILES TRANSNATIONAL CORPORATION 
      10.33.1 OVERVIEW 
      10.33.2 FINANCIALS 
      10.33.3 PRODUCTS & SERVICES 
      10.33.4 STRATEGY 
      10.33.5 DEVELOPMENTS 
  10.34 QIAGEN NV 
      10.34.1 OVERVIEW 
      10.34.2 FINANCIALS 
      10.34.3 PRODUCTS & SERVICES 
      10.34.4 STRATEGY 
      10.34.5 DEVELOPMENTS 
  10.35 ROCHE DIAGNOSTICS LIMITED
      10.35.1 OVERVIEW
      10.35.2 FINANCIALS
      10.35.3 PRODUCTS & SERVICES
      10.35.4 STRATEGY
      10.35.5 DEVELOPMENT
  10.36 SANOFI-AVENTIS
      10.36.1 OVERVIEW
      10.36.2 FINANCIALS
      10.36.3 PRODUCTS & SERVICES
      10.36.4 STRATEGY
      10.36.5 DEVELOPMENT
  10.37 SIEMENS HEALTHCARE
      10.37.1 OVERVIEW
      10.37.2 FINANCIALS
      10.37.3 PRODUCTS & SERVICES
      10.37.4 STRATEGY
      10.37.5 DEVELOPMENTS
  10.38 TRANS-HIT BIOMARKERS INC
      10.38.1 OVERVIEW
      10.38.2 FINANCIALS
      10.38.3 PRODUCTS & SERVICES
      10.38.4 STRATEGY
      10.38.5 DEVELOPMENTS
  10.39 PACIFIC BIOMARKERS INC
      10.39.1 OVERVIEW
      10.39.2 FINANCIALS
      10.39.3 PRODUCTS & SERVICES
      10.39.4 STRATEGY
      10.39.5 DEVELOPMENTS
  10.40 CAPRION PROTEOMICS INC.
      10.40.1 OVERVIEW
      10.40.2 FINANCIALS
      10.40.3 PRODUCTS & SERVICES
      10.40.4 STRATEGY
      10.40.5 DEVELOPMENTS
  10.41 PROTEOME SCIENCES PLC
      10.41.1 OVERVIEW
      10.41.2 FINANCIALS
      10.41.3 PRODUCTS & SERVICES
      10.41.4 STRATEGY
      10.41.5 DEVELOPMENTS
  10.42 VERMILLION INC
      10.42.1 OVERVIEW
      10.42.2 FINANCIALS
      10.42.3 PRODUCTS & SERVICES
      10.42.4 STRATEGY
      10.42.5 DEVELOPMENTS  
   
LIST OF TABLES  
  
TABLE 1 GLOBAL BIOMARKERS MARKET REVENUE, BY SEGMENTS, 2009 – 2020 ($MILLION) 
TABLE 2 GLOBAL BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION)  
TABLE 3 GLOBAL BIOMARKERS DISCOVERY MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)  
TABLE 4 BIOMARKERS DISCOVERY TECHNOLOGIES MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION) 
TABLE 5 GLOBAL BIOMARKERS DISCOVERY MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION) 
TABLE 6 BIOMARKERS IMAGING TECHNOLOGIES MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION)  
TABLE 7 GLOBAL BIOMARKERS DISCOVERY MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION) 
TABLE 8 GLOBAL BIOMARKERS OMICS TECHNOLOGIES MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)  
TABLE 9  BIOMARKERS OMICS TECHNOLOGIES MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION)  
TABLE 10 GLOBAL PROTEOMICS BIOMARKERS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)  
TABLE 11 GLOBAL GENOMICS BIOMARKERS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)  
TABLE 12 GLOBAL TRANSCRIPTOMICS BIOMARKERS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION) 
TABLE 13 GLOBAL METABOLOMICS BIOMARKERS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)  
TABLE 14 GLOBAL BIOMARKERS BIOINFORMATICS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION) 
TABLE 15 BIOMARKERS BIOINFORMATICS MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION) 
TABLE 16 GLOBAL BIOMARKERS MARKET, BY APPLICATIONS, 2009 – 2020 ($MILLION) 
TABLE 17 GLOBAL BIOMARKERS APPLICATION MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)  
TABLE 18 BIOMARKERS APPLICATION MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION) 
TABLE 19 GLOBAL BIOMARKERS DRUG DISCOVERY & DEVELOPMENT PROCESS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION) 
TABLE 20 BIOMARKERS DRUG DISCOVERY & DEVELOPMENT PROCESS MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION)  
TABLE 21 GLOBAL BIOMARKERS APPLICATION MARKET, BY PHASES IN DRUG DISCOVERY & DEVELOPMENT PROCESS, 2009 – 2020 ($MILLION) 
TABLE 22 GLOBAL BIOMARKERS PRECLINICAL STUDY MARKET, BY VARIOUS INDICATIONS, 2009 – 2020 ($MILLION)  
TABLE 23 GLOBAL BIOMARKERS PHASE I MARKET, BY PHASES IN VARIOUS INDICATIONS, 2009 – 2020 ($MILLION) 
TABLE 24 GLOBAL BIOMARKERS PHASE II MARKET, BY PHASES IN VARIOUS INDICATIONS, 2009 – 2020 ($MILLION) 
TABLE 25 GLOBAL BIOMARKERS PHASE III MARKET, BY PHASES IN VARIOUS INDICATIONS, 2009 – 2020 ($MILLION) 
TABLE 26 GLOBAL BIOMARKERS PHASE IV MARKET, BY PHASES IN VARIOUS INDICATIONS, 2009 – 2020 ($MILLION) 
TABLE 27 PERSONALIZED MEDICINE(PM) USING BIOMARKERS IN CURRENT DRUG LABELS 
TABLE 28 GLOBAL BIOMARKERS PERSONALIZED MEDICINE MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)  
TABLE 29 BIOMARKERS PERSONALIZED MEDICINE MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION)  
TABLE 30 GLOBAL MOLECULAR DIAGNOSTICS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)  
TABLE 31 MOLECULAR DIAGNOSTICS MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION)  
TABLE 32 GLOBAL BIOMARKERS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)  
TABLE 33 GLOBAL ONCOLOGY BIOMARKERS MARKET, BY SEGMENTS, 2009 – 2020 ($MILLION)  
TABLE 34 GLOBAL ONCOLOGY BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION) 
TABLE 35 GLOBAL ONCOLOGY BIOMARKERS MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION) 
TABLE 36 GLOBAL ONCOLOGY BIOMARKERS MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION) 
TABLE 37 GLOBAL ONCOLOGY BIOMARKERS MARKET, BY PHASES, 2009 – 2020 ($MILLION)  
TABLE 38 GLOBAL ONCOLOGY BIOMARKERS MARKET, BY CANCER TYPES, 2009 – 2020 ($MILLION)  
TABLE 39 ONCOLOGY BIOMARKERS MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION)  
TABLE 40 GLOBAL CARDIOLOGY BIOMARKERS MARKET REVENUE, BY SEGMENTS, 2009 – 2020 ($MILLION) 
TABLE 41 GLOBAL CARDIOLOGY BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION) 
TABLE 42 GLOBAL CARDIOLOGY BIOMARKERS MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION) 
TABLE 43 GLOBAL CARDIOLOGY BIOMARKERS MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION) 
TABLE 44 GLOBAL CARDIOLOGY BIOMARKERS MARKET, BY PHASES, 2009 – 2020 ($MILLION)  
TABLE 45 GLOBAL CARDIOLOGY BIOMARKERS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)  
TABLE 46 COMMONLY USED CARDIAC BIOMARKERS TESTS 
TABLE 47 BIOMARKERS TESTS USED FOR PROGNOSIS 
TABLE 48 CARDIAC MARKERS MARKET REVENUE, BY GEOGRAPHY, 2009 – 2020 ($MILLION)  
TABLE 49 GLOBAL NEUROLOGY BIOMARKERS MARKET, BY SEGMENTS, 2009 – 2020 ($MILLION)  
TABLE 50 GLOBAL NEUROLOGY BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION) 
TABLE 51 GLOBAL NEUROLOGY BIOMARKERS MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION) 
TABLE 52 GLOBAL NEUROLOGY BIOMARKERS MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION) 
TABLE 53 GLOBAL  NEUROLOGY BIOMARKERS MARKET, BY PHASES, 2009 – 2020 ($MILLION)  
TABLE 54 GLOBAL NEUROLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009– 2020 ($MILLION)  
TABLE 55 NEUROLOGY BIOMARKERS MARKET, BY GEOGRAPHY, 2009 – 2020 ($MILLION)  
TABLE 56 GLOBAL OTHER INDICATIONS BIOMARKERS MARKET, BY SEGMENTS, 2009 – 2020 ($MILLION) 
TABLE 57 GLOBAL OTHER INDICATIONS BIOMARKERS MARKET REVENUE, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION)  
TABLE 58 GLOBAL OTHER INDICATIONS BIOMARKERS MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION)  
TABLE 59 GLOBAL OTHER INDICATIONS BIOMARKERS MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION)  
TABLE 60 GLOBAL OTHER INDICATIONS BIOMARKERS MARKET, BY PHASES, 2009 – 2020 ($MILLION)  
TABLE 61 GLOBAL OTHER INDICATIONS BIOMARKERS MARKET, BY TYPES, 2009 – 2020 ($MILLION)  
TABLE 62 HIV BIOMARKERS 
TABLE 63 RENAL BIOMARKERS 
TABLE 64 OTHER INDICATIONS MARKET REVENUE, BY GEOGRAPHY, 2009 – 2020 ($MILLION)  
TABLE 65 BIOMARKERS MARKET REVENUE, BY GEOGRAPHY, 2009 – 2020 ($BILLION)  
TABLE 66 NORTH AMERICA: BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION) 
TABLE 67 NORTH AMERICA: BIOMARKERS MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION) 
TABLE 68 NORTH AMERICA: BIOMARKERS MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION) 
TABLE 69 NORTH AMERICA: BY APPLICATIONS, 2009 – 2020 ($MILLION)  
TABLE 70 NORTH AMERICA: BY DRUG DISCOVERY & DEVELOPMENT, 2009 – 2020 ($MILLION) 
TABLE 71 NORTH AMERICA: BY INDICATIONS, 2009 – 2020 ($MILLION)  
TABLE 72 NORTH AMERICA: ONCOLOGY BIOMARKERS MARKET, BY CANCER TYPES, 2009 – 2020 ($MILLION)  
TABLE 73 NORTH AMERICA: BIOMARKERS MARKET, CARDIOLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009 – 2020 ($MILLION)  
TABLE 74 NORTH AMERICA: NEUROLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009 – 2020 ($MILLION)  
TABLE 75 NORTH AMERICA: OTHER INDICATIONS BIOMARKERS MARKET, BY TYPES, 2009 – 2020 ($MILLION)  
TABLE 76 EUROPE: BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION)  
TABLE 77 EUROPE: BIOMARKERS MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION)  
TABLE 78 EUROPE: BIOMARKERS MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION)  
TABLE 79 EUROPE: BY APPLICATIONS, 2009 – 2020 ($MILLION)  
TABLE 80 EUROPE: BY DRUG DISCOVERY & DEVELOPMENT, 2009 – 2020 ($MILLION) 
TABLE 81 EUROPE: BY INDICATIONS, 2009 – 2020 ($MILLION)  
TABLE 82 EUROPE: BIOMARKERS MARKET, ONCOLOGY BIOMARKERS MARKET, BY CANCER TYPES, 2009 – 2020 ($MILLION)  
TABLE 83 EUROPE: CARDIOLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009 – 2020 ($MILLION)  
TABLE 84 EUROPE: NEUROLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009 – 2020 ($MILLION)  
TABLE 85 EUROPE: OTHER INDICATIONS BIOMARKERS MARKET, BY TYPES, 2009 – 2020 ($MILLION)  
TABLE 86 ASIA: BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION)  
TABLE 87 ASIA: BIOMARKERS MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION)  
TABLE 88 ASIA: BIOMARKERS MARKET, BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION)  
TABLE 89 ASIA: BY APPLICATIONS, 2009 – 2020 ($MILLION)  
TABLE 90 ASIA: BY DRUG DISCOVERY & DEVELOPMENT, 2009 – 2020 ($MILLION) 
TABLE 91 ASIA: BY INDICATIONS, 2009 – 2020 ($MILLION)  
TABLE 92 ASIA: ONCOLOGY BIOMARKERS MARKET, BY CANCER TYPES, 2009 – 2020 ($MILLION)  
TABLE 93 ASIA: CARDIOLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009 – 2020 ($MILLION)  
TABLE 94 ASIA: BIOMARKERS MARKET, NEUROLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009 – 2020 ($MILLION)  
TABLE 95 ASIA: OTHER INDICATIONS BIOMARKERS MARKET, BY TYPES, 2009 – 2020 ($MILLION)  
TABLE 96 ROW: BIOMARKERS MARKET, BIOMARKERS MARKET, BY DISCOVERY TECHNOLOGIES, 2009 – 2020 ($MILLION)  
TABLE 97 ROW: BIOMARKERS MARKET, BY OMICS TECHNOLOGIES, 2009 – 2020 ($MILLION)  
TABLE 98 ROW: BY IMAGING TECHNOLOGIES, 2009 – 2020 ($MILLION)  
TABLE 99 ROW: BY APPLICATIONS, 2009 – 2020 ($MILLION)  
TABLE 100 ROW: BY DRUG DISCOVERY & DEVELOPMENT, 2009 – 2020 ($MILLION) 
TABLE 101 ROW: BIOMARKERS MARKET, BY INDICATIONS, 2009 – 2020 ($MILLION)  
TABLE 102 ROW: ONCOLOGY BIOMARKERS MARKET, BY CANCER TYPES, 2009 – 2020 ($MILLION)  
TABLE 103 ROW: BIOMARKERS MARKET, CARDIOLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009 – 2020 ($MILLION)  
TABLE 104 ROW: NEUROLOGY BIOMARKERS MARKET, BY DISEASE TYPES, 2009 – 2020 ($MILLION)  
TABLE 105 ROW: OTHER INDICATIONS BIOMARKERS MARKET, BY TYPES, 2009 – 2020 ($MILLION)  
TABLE 106 MERGERS & ACQUISITIONS (JANUARY 2009 – DECEMBER 2011) 
TABLE 107 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES (JANUARY 2009 – DECEMBER 2011) 
TABLE 108 NEW PRODUCTS LAUNCH (JANUARY 2009 – DECEMBER 2011) 
TABLE 109 OTHER DEVELOPMENTS (JANUARY 2009 – DECEMBER 2011) 
TABLE 110 ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)  
TABLE 111 ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION) 
TABLE 112 ABBOTT LABORATORIES: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) 
TABLE 113 AFFYMETRIX INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) 
TABLE 114 AFFYMETRIX INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION) 
TABLE 115 AFFYMETRIX INC: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) 
TABLE 116 AGILENT TECHNOLOGIES INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) 
TABLE 117 AGILENT TECHNOLOGIES INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)  
TABLE 118 AGILENT TECHNOLOGIES INC: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) 
TABLE 119 AMGEN INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) 
TABLE 120 AMGEN INC: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) 
TABLE 121 ASTRAZENECA PLC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) 
TABLE 122 ASTRAZENECA PLC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION) 
TABLE 123 ASTRAZENECA PLC: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) 
TABLE 124 BAYER AG: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) 
TABLE 125 BAYER AG: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION) 
TABLE 126 BAYER AG: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) 
TABLE 127 BECKMAN COULTER INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)  
TABLE 128 BECKMAN COULTER INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)  
TABLE 129 BECKMAN COULTER INC: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) 
TABLE 130 BRISTOL-MYERS SQUIBB: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)  
TABLE 131 BRISTOL-MYERS SQUIBB: TOTAL REVENUES, BY SEGMENTS, 2008 – 2010 ($MILLION)  
TABLE 132 BRISTOL-MYERS SQUIBB: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) 
TABLE 133 EISAI CO. LTD: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)  
TABLE 134 EISAI CO. LTD: TOTAL REVENUES, BY SEGMENTS, 2009 – 2011 ($MILLION) 
TABLE 135 EISAI CO. LTD: REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION) 
TABLE 136 EPISTEM HOLDINGS PLC: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)  
TABLE 137 EPISTEM HOLDINGS PLC: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION)  
TABLE 138 EPISTEM HOLDINGS PLC: REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)  
TABLE 139 EVOTEC AG: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)  
TABLE 140 EVOTEC AG: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) 
TABLE 141 GLAXOSMITHKLINE PLC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2011 ($MILLION)  
TABLE 142 GLAXOSMITHKLINE PLC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2011 ($MILLION)  
TABLE 143 GLAXOSMITHKLINE PLC: REVENUE FOR PHARMACEUTICAL SEGMENT, BY GEOGRAPHY, 2008 – 2011 ($MILLION) 
TABLE 144 IPSEN: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) 
TABLE 145 IPSEN: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION) 
TABLE 146 IPSEN: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) 
TABLE 147 JOHNSON & JOHNSON: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)  
TABLE 148 JOHNSON & JOHNSON: TOTAL REVENUE, BY SEGMENTS, 2008 -2010 ($MILLION) 
TABLE 149 MEDICAL DEVICES & DIAGNOSTICS SEGMENT REVENUE, 2008 – 2010 ($MILLION) 
TABLE 150 JOHNSON & JOHNSON: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) 
TABLE 151 MERCK & CO: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) 
TABLE 152 MERCK & CO: TOTAL REVENUES, BY SEGMENTS, 2008 – 2010 ($MILLION) 
TABLE 153 MERCK & CO: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) 
TABLE 154 MYRIAD GENETICS INC: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)  
TABLE 155 MYRIAD GENETICS INC: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION)  
TABLE 156 NEXTGEN GROUP PLC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)  
TABLE 157 NEXTGEN GROUP PLC: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) 
TABLE 158 NOVARTIS INTERNATIONAL AG: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) 
TABLE 159 NOVARTIS INTERNATIONAL AG: TOTAL REVENUES, BY SEGMENTS, 2008 – 2010 ($MILLION) 
TABLE 160 NOVARTIS INTERNATIONAL AG: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)  
TABLE 161 PFIZER INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION) 
TABLE 162 PFIZER INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION) 
TABLE 163 PFIZER INC: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) 
TABLE 164 QIAGEN N.V: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)  
TABLE 165 QIAGEN N.V.: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)  
TABLE 166 QIAGEN N.V.: GEOGRAPHIC REVENUES, 2008 – 2010 ($MILLION) 
TABLE 167 ROCHE: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)  
TABLE 168 ROCHE: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION) 
TABLE 169 SANOFI-AVENTIS: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)  
TABLE 170 SANOFI-AVENTIS: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)  
TABLE 171 SANOFI-AVENTIS: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) 
TABLE 172 SIEMENS: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)  
TABLE 173 SIEMENS: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION) 
TABLE 174 SIEMENS: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION) 
TABLE 175 PROTEOME SCIENCES PLC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)  
TABLE 176 PROTEOME SCIENCES PLC: REVENUE, BY GEOGRAPHY, 2008 – 2010 ($MILLION)  
TABLE 177 VERMILLION INC: TOTAL REVENUE AND R&D EXPENSES, 2008 – 2010 ($MILLION)  
TABLE 178 VERMILLION INC: TOTAL REVENUE, BY SEGMENTS, 2008 – 2010 ($MILLION)  
  
   
LIST OF FIGURES   
  
FIGURE 1 OVERVIEW OF BIOMARKERS MARKET 
FIGURE 2 LIFE CYCLE OF A BIOMARKERS 
FIGURE 3 BIOMARKERS MARKET 
FIGURE 4 LEVEL OF IMPACT OF CHALLENGES 
FIGURE 5 BIOMARKERS DISCOVERY PROCESS 
FIGURE 6 BIOMARKERS DISCOVERY MARKET, 2011 
FIGURE 7 OMICS TECHNOLOGIES & THE CENTRAL DOGMA 
FIGURE 8 BIOMARKERS DISCOVERY MARKET, BY OMICS TECHNOLOGIES, 2011 
FIGURE 9 THE CENTRAL ROLE OF MASS SPECTROMETRY IN PROTEOMICS 
FIGURE 10 BIOMARKERS DISCOVERY USING 2-D DIGE & MS 
FIGURE 11 TRANSCRIPTOMICS BIOMARKERS DISCOVERY 
FIGURE 12 BIOINFORMATICS MICROARRAY TOOLS 
FIGURE 13 CLUSTER ANALYSIS OF OMICS DATA FOR BIOMARKERS DISCOVERY 
FIGURE 14 BIOMARKERS SERVICES MARKET, BY SEGMENTS (%) 
FIGURE 15 FLOW OF CLINICAL BIOMARKERS SERVICES 
FIGURE 16 DRUG DISCOVERY & DEVELOPMENT PROCESS 
FIGURE 17 BIOMARKERS DISCOVERY, BY INDICATIONS, 2011 
FIGURE 18 KEY GROWTH STRATEGIES (JANUARY 2009 – DECEMBER 2011)

Biomarkers comprise definite cells, genes, molecules, gene products, enzymes, or hormones which are objectively measured as an indicator of typical biological processes, pathogenic processes, or pharmacologic response to a therapeutic intrusion. Major application areas of biomarkers are early disease diagnosis and prevention, drug target recognition, and drug discovery and development. The global market showcases high growth potential in the near future. This market is expected to grow at a CAGR of 18.5% from 2013 to 2018, to reach $40.8 billion by 2018.

The global market has been segmented into biomarker discovery technologies, biomarker services, applications, and disease indications. The biomarker discovery technologies are classified as omics technology, imaging technology, and bioinformatics. Omics technology, which includes proteomics, genomics, transcriptomics, and metabolomics, accounts for the largest share of the biomarker discovery technology market. The biomarkers services market is classified into sample preparation, assay development, and biomarker validation and testing services. Biomarkers applications market has been segmented as drug discovery and development, molecular diagnostics, and personalized medicine. Based on type of diseases, the biomarkers disease indication market has been classified as oncology, cardiology, neurology, and other diseases (HIV, renal disorders, diabetes, arthritis, and tuberculosis).

Globally, the market is witnessing a transformation and is expected to grow at a high growth rate in the coming years. The growth in the market will be primarily driven by advancements in discovery technologies, government initiatives and grants for biomarker research activities, and rising demand for personalized medicine. The incidence and prevalence of chronic diseases such as cancer, cardiac diseases, and diabetes is increasing globally and hence, it is crucial to develop new preventive and diagnostics treatments. Since, biomarkers play a significant role in development of preventive and diagnostic tests and drugs, the demand of biomarkers is expected to increase rapidly.

Over the past few years, the biomarkers industry has been witnessing increasing number of contracts and partnership agreements among market players for the development of novel biomarkers. Major research on biomarkers is taking place in the field of oncology. Recent developments of companies such as Thermo Fisher Scientific, Inc. (U.S.), QIAGEN N.V. (Netherlands), Roche Diagnostics (Switzerland), Hologic, Inc. (U.S.), and Johnson & Johnson (U.S.) have exhibited inclination towards agreements and partnerships, in accordance to their key strategy to expand their market share and geographical presence.

However, a few pivotal factors hindering the growth of this market are high capital investment, low benefit-cost ratio, and cumbersome biomarker validation and testing process. In addition, the complex sample collection and storage procedure is also a major challenge faced by industry players.

Biomarker research activities rate is high in emerging countries such as China and India attributed to a number of factors such as the increasing number of contract research organizations and the low cost of conducting clinical trials in Asia-Pacific economies as compared to developed countries. These factors are compelling the established as well as new companies to focus on emerging markets for their biomarkers discovery and development research activities.

The key players in this market are Roche Diagnostics Limited (Switzerland), Johnson & Johnson (U.S.), GlaxoSmithKline, Plc. (U.K.), Siemens Healthcare (Germany), Abbott Laboratories, Inc. (U.S.), GE Healthcare (U.K.), Affymetrix, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Epigenomics AG (Germany), Eisai Co. Ltd. (Japan), Bio-Rad Laboratories, Inc. (U.S.), Eli Lilly and Company (U.S.), Merck & Co. (U.S.), Genomic Health, Inc. (U.S.), and Agilent Technologies Inc. (U.S.)

GLOBAL BIOMARKERS MARKET, BY SEGMENTS, 2013

Biomarkers Market

Source: Annual Reports, SEC Filings, Press Releases, Expert Interviews, and MarketsandMarkets Analysis

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports